FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for detecting HER2 positive subtype of breast cancer (BC). Blood is separately incubated in a nutrient medium in samples with and without the addition of a cancer-embryonic antigen (CEA), obtaining supernatant in each of two samples with CEA and without CEA and determination of concentration of granulocyte-macrophage colony-stimulating factor (GM-CSF) in each of samples. An index of CEA effect (EICEA) on production of GM-CSF by blood cells is calculated. If EICEA is equal to or greater than 10.4, HER2 positive subtype of breast cancer is diagnosed.
EFFECT: method provides high accuracy of detecting the HER2 positive subtype of breast cancer with low invasiveness of the method by determining the CEA effect index on the production of GM-CSF by the patient's blood cells.
1 cl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF HORMONE DEPENDENCE OF BREAST CANCER IN PRIMARY MENOPAUSAL PATIENTS | 2014 |
|
RU2562538C2 |
| METHOD OF PREDICTING RESISTANCE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2802671C1 |
| METHOD OF DETERMINING THE CONVERSION OF THE MOLECULAR BIOLOGICAL SUBTYPE OF THE TOTALITY OF CIRCULATING TUMOR CELLS RELATIVE TO THE MOLECULAR BIOLOGICAL SUBTYPE OF THE PRIMARY TUMOR IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2797698C1 |
| METHOD OF PREDICTING HIGH RISK OF REGIONAL METASTASIS IN BREAST CANCER | 2023 |
|
RU2816441C1 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD FOR PREDICTING THE COURSE OF A PATHOLOGICAL PROCESS IN LUMINAL NON-HYPEREXPRESSION OF Her2Neu PRIMARY OPERABLE BREAST CANCER IN POSTMENOPAUSAL WOMEN | 2018 |
|
RU2694843C1 |
| METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
| METHOD FOR PREDICTION OF OCCURRENCE OF LOCAL RECURRENCES IN POSTOPERATIVE PERIOD IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER | 2020 |
|
RU2734719C1 |
| METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
